CVR: 31853923
Previous names: STENO DIABETES CENTER A/S
Novo Nordisk Invest 4 A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 2008. The company is registered under the industry Ikke-finansielle holdingselskaber. The company was previously named STENO DIABETES CENTER A/S. The management consists of Anders Rytter Mikkelsen. The company is owned by NOVO NORDISK A/S. The company has 0 employees. In 2025, the company reported a gross profit of DKK -64,000 and a net result of DKK -23,000 compared with DKK 7,000 the year before. Equity amounted to DKK 1,772,000.
Your company? Claim the profile and show your logo, website and social channels — for free.
Claim this profileSelskabets formål er at besidde ejerandele i selskaber i ind- og udland, at foretage investerings- og finansieringsvirksomhed, herunder anbringelse af kapital i virksomheder og fast ejendom i ind- og udland samt efter bestyrelsens nærmere bestemmelse at servicere sådanne selskaber og virksomheder driftsmæssigt.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | - | -23 t. | 1.8 mio. | 1.8 mio. | 0 | |
| 2024 | - | 7 t. | 1.8 mio. | 1.8 mio. | - | |
| 2023 | - | 5 t. | 1.8 mio. | 1.8 mio. | - | |
| 2022 | - | 4 t. | 2 mio. | 1.8 mio. | - | |
| 2021 | - | -37 t. | 2.2 mio. | 1.8 mio. | - | |
| 2020 | - | -108 t. | 2.3 mio. | 1.8 mio. | - | |
| 2019 | - | -398 t. | 9.2 mio. | 8.9 mio. | - | |
| 2018 | - | 189 t. | 10.2 mio. | 9.3 mio. | - | |
| 2017 | - | -775 t. | 11.6 mio. | 9.1 mio. | - | |
| 2016 | - | -407 t. | 85.5 mio. | 9.9 mio. | - | |
| 2015 | 219.3 mio. | 803 t. | 86.7 mio. | 10.3 mio. | - | |
| 2013 | 181.8 mio. | -214 t. | 66.8 mio. | 5.7 mio. | - |
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationCompared to 50.000 companies in Ikke-finansielle holdingselskaber
Comparison is based on industry median values
Novo Nordisk Invest 4 A/S has published its annual report for 2025. Gross profit came to DKK -64,000, and the net result was DKK -23,000.
Contact info changed: new phone: 44448888 (May 13, 2026).
As of May 12, 2026, Anders Rytter Mikkelsen is registered as director of Novo Nordisk Invest 4 A/S.
As of May 12, 2026, Peter Bøggild has stepped down as director of Novo Nordisk Invest 4 A/S.
As of December 8, 2025, Naja Eilers Barrisøe has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of December 8, 2025, Karsten Munk Knudsen has left the board of directors of Novo Nordisk Invest 4 A/S.
Novo Nordisk Invest 4 A/S has published its annual report for 2024. Gross profit came to DKK -55,000, and the net result was DKK 7,000.
Novo Nordisk Invest 4 A/S has published its annual report for 2023. Gross profit came to DKK -53,000, and the net result was DKK 5,000.
As of May 23, 2024, John Francis Kuckelman has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of May 23, 2024, Kristine Aachmann Bethe has left the board of directors of Novo Nordisk Invest 4 A/S.
As of June 30, 2023, Kristine Aachmann Bethe has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of June 30, 2023, Tomas Haagen has left the board of directors of Novo Nordisk Invest 4 A/S.
Novo Nordisk Invest 4 A/S has published its annual report for 2022. Gross profit came to DKK -6,000, and the net result was DKK 4,000.
Novo Nordisk Invest 4 A/S has published its annual report for 2021. The net result was DKK -37,000.
Novo Nordisk Invest 4 A/S has published its annual report for 2020. The net result was DKK -108,000.
As of May 12, 2021, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Novo Nordisk Invest 4 A/S.
As of May 12, 2021, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Novo Nordisk Invest 4 A/S.
As of December 15, 2020, Linette Tangsgaard Nielsen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of December 15, 2020, Lene Moth Bang has left the board of directors of Novo Nordisk Invest 4 A/S.
Novo Nordisk Invest 4 A/S has published its annual report for 2019. The net result was DKK -398,000.
Novo Nordisk Invest 4 A/S has published its annual report for 2018. The net result was DKK 189,000.
As of October 1, 2018, Tomas Haagen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of October 1, 2018, Ole Falvig Ramsby has left the board of directors of Novo Nordisk Invest 4 A/S.
Novo Nordisk Invest 4 A/S has published its annual report for 2017. The net result was DKK -775,000.
As of April 25, 2018, Karsten Munk Knudsen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of April 25, 2018, Jesper Brandgaard has left the board of directors of Novo Nordisk Invest 4 A/S.
As of April 25, 2018, Peter Bøggild is registered as director of Novo Nordisk Invest 4 A/S.
As of April 25, 2018, Karsten Munk Knudsen has stepped down as director of Novo Nordisk Invest 4 A/S.
As of June 1, 2017, Lene Moth Bang has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of June 1, 2017, Lars Fruergaard Jørgensen has left the board of directors of Novo Nordisk Invest 4 A/S.
Novo Nordisk Invest 4 A/S has published its annual report for 2016. The net result was DKK -407,000.
As of January 1, 2017, Ole Falvig Ramsby has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Jesper Brandgaard has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Lars Fruergaard Jørgensen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Anne Birgitte Urup Hemmingsen has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Birgitte Nauntofte has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Kirsten Engelhard Nielsen has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Mads Krogsgaard Thomsen has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Søren Thor Jensen has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Nana Folmann Hempler has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Majken Borup Linnemann Jensen has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Kristine Færch has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Alan Charles Moses has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Bo Ahrén has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Karsten Munk Knudsen is registered as director of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, John James Nolan has stepped down as director of Novo Nordisk Invest 4 A/S.
On January 1, 2017, the company changed its name from STENO DIABETES CENTER A/S to Novo Nordisk Invest 4 A/S.
Novo Nordisk Invest 4 A/S has published its annual report for 2015. Revenue came to DKK 219,295,000, and the net result was DKK 803,000.
Novo Nordisk Invest 4 A/S has published its annual report for 2014.
As of December 9, 2014, Peter Jens Lindholm Kurtzhals has left the board of directors of Novo Nordisk Invest 4 A/S.
As of November 27, 2014, Mads Krogsgaard Thomsen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of November 27, 2014, Lars Rebien Sørensen has left the board of directors of Novo Nordisk Invest 4 A/S.
As of November 25, 2014, Lars Rebien Sørensen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of November 25, 2014, Lise Kingo has left the board of directors of Novo Nordisk Invest 4 A/S.
Novo Nordisk Invest 4 A/S has published its annual report for 2013. Revenue came to DKK 181,767,000, and the net result was DKK -214,000.
Novo Nordisk Invest 4 A/S has published its annual report for 2012.
As of March 22, 2013, Nana Folmann Hempler has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of March 22, 2013, Majken Borup Linnemann Jensen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of March 22, 2013, Kristine Færch has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of March 22, 2013, Bo Ahrén has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of March 22, 2013, Dorthe Tecza has left the board of directors of Novo Nordisk Invest 4 A/S.
As of March 22, 2013, Peder Rasmussen has left the board of directors of Novo Nordisk Invest 4 A/S.
As of March 22, 2013, Niels Borregaard has left the board of directors of Novo Nordisk Invest 4 A/S.
As of March 22, 2012, Søren Thor Jensen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of March 22, 2012, Ole Falvig Ramsby has left the board of directors of Novo Nordisk Invest 4 A/S.
As of November 10, 2011, Alan Charles Moses has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of July 1, 2011, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Novo Nordisk Invest 4 A/S.
As of July 1, 2011, A/S PSE NR. 4820 has stepped down as auditor of Novo Nordisk Invest 4 A/S.
As of March 15, 2011, Birgitte Nauntofte has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of March 15, 2011, Martinus Hermanus Soeters has left the board of directors of Novo Nordisk Invest 4 A/S.
As of February 10, 2011, Dorthe Tecza has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of February 10, 2011, Allan Arthur Vaag has left the board of directors of Novo Nordisk Invest 4 A/S.
As of February 10, 2011, Dorthe Tecza has left the board of directors of Novo Nordisk Invest 4 A/S.
As of February 10, 2011, Charlotte Brøns has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2011, John James Nolan is registered as director of Novo Nordisk Invest 4 A/S.
As of January 1, 2011, Knut Borch-Johnsen has stepped down as director of Novo Nordisk Invest 4 A/S.
As of November 3, 2009, Gert Almind Frederiksen has left the board of directors of Novo Nordisk Invest 4 A/S.
As of April 22, 2009, Allan Arthur Vaag has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of April 22, 2009, Anne Birgitte Urup Hemmingsen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of April 22, 2009, Dorthe Tecza has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of April 22, 2009, Peder Rasmussen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of April 22, 2009, Charlotte Brøns has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of April 22, 2009, Kirsten Engelhard Nielsen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of January 16, 2009, Gert Almind Frederiksen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of January 16, 2009, Niels Borregaard has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of January 16, 2009, Lise Kingo has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of January 16, 2009, Peter Jens Lindholm Kurtzhals has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of January 16, 2009, Martinus Hermanus Soeters has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of January 16, 2009, Lars Rebien Sørensen has left the board of directors of Novo Nordisk Invest 4 A/S.
As of November 17, 2008, A/S PSE NR. 4820 has been appointed auditor of Novo Nordisk Invest 4 A/S.
As of November 17, 2008, Ole Falvig Ramsby has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of November 17, 2008, Lars Rebien Sørensen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of November 17, 2008, Knut Borch-Johnsen is registered as director of Novo Nordisk Invest 4 A/S.
As of November 17, 2008, NOVO NORDISK A/S is registered as an owner of Novo Nordisk Invest 4 A/S with an ownership share of 100%.
Novo Nordisk Invest 4 A/S was founded on November 17, 2008.
Companies in the same industry and area
CVR 37868957
CVR 33392982
CVR 39866471
CVR 33862954
CVR 44591812
companydata.dk